News

As per the collaboration, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and thereby help Ono’s structure-based drug

The two bispecific antibodies were developed using the company’s protein conjugation technology, Dock-and-Lock (DNL). The two anti-CD20/CD74 antibodies showed inhibition in the growth of MCL cell lines, as

Veltuzumab, a humanized anti-CD20 antibody was constructed using the same human donor frameworks as epratuzumab. The results demonstrated that two doses of veltuzumab produced an overall objective response

Mydicar is a genetically targeted enzyme replacement therapy designed to restore levels of SERCA2a, that regulates calcium cycling and contractility. The randomized double-blind placebo-controlled Phase 2 Calcium Up-regulation

The siRNA liposome technique is used in biology laboratories to enable in vivo delivery of siRNA and uses microfluidizer (Microfluidics) technology. According to the company, in vivo siRNA-induced

According to Ablynx, this is the first pre-clinical candidate that has emerged from the collaboration. Ablynx is entitled to a milestone payment of EUR1m, under the terms of

AIMs activate the transcription factor Nrf2, that suppresses NF-?B, a transcription factor that is associated with chronic diseases such as multiple sclerosis, rheumatoid arthritis, chronic kidney disease, neurodegenerative

The new web-based technology is believed to help in effective research, where data will be translated into innovative products thereby bringing a growth in the economy, bdaily.co.uk reported.

The company will use the proceeds of the financing for the completion of its ongoing Phase II trial of the improved formulation of antidepressant TriRima, besides using it